drugset / Trial / NCT01307267
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
Timeline
- Start
- 2011-06-21
- Primary completion
- 2019-02-20
- Completion
- 2019-02-20
Publications
- Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. doi: 10.1158/1078-0432.CCR-19-2973. Epub 2020 Mar 6.
- Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Utomilumab | Monoclonal antibody | 0.006 mg/kg | Intravenous |
| Subject | Utomilumab | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | Utomilumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Utomilumab | Monoclonal antibody | 0.6 mg/kg | Intravenous |
| Subject | Utomilumab | Monoclonal antibody | 1.2 mg/kg | Intravenous |
| Subject | Utomilumab | Monoclonal antibody | 10 mg/kg | Intravenous |